In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.

The defendants listed include the drug manufacturers Eli Lilly, Novo Nordisk and Sanofi Aventis U.S., and PBM and group purchasing organization affiliates of Cigna's Evernorth Health unit ...

They’re followed by Lilly, Johnson & Johnson, Novo, AstraZeneca, Novartis, Pfizer and finally Sanofi in the projected rankings. In terms of drug sales buoying those company rankings, Lilly’s ...

It said that may be at odds with the FDA's view. Insurers generally cover Lilly's and Novo's drugs for diabetes, but many do not cover the weight-loss medications. That has led many patients to ...

In this photo is a Zepbound injection pen ... Novo Nordisk's Wegovy (semaglutide),” GlobalData said in a report the market research firm released Tuesday. “Recently, Eli Lilly announced ...

α-Glucosidase inhibitors 0.5 0.8 Weight neutral Frequent GI side effects, three times/day dosing, expensive Exenatide 0.5 1.0 Weight loss Injections, frequent GI side effects, expensive, little ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive signals” are emerging when it comes to the consistent supply of GLP-1 ...

Eli Lilly has been riding the weight-loss drug wave ... weight using Mounjaro versus 6% for patients prescribed Ozempic. Novo Nordisk, the maker of Ozempic, has questioned the reported results ...

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo Nordisk (NVO), its closest rival in the lucrative obesity drug market ...